Anika Therapeutics Inc. P/Operating CF

P/Operating CF of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/Operating CF of Anika Therapeutics Inc. is 235.8 (as of December 30, 2020)
  • P/Operating CF for the quarter ending September 29, 2021 was 249.63 (a 90.63% increase compared to previous quarter)
  • Year-over-year quarterly P/Operating CF increased by 5.87%
  • Annual P/Operating CF for 2020 was 235.8 (a 319.38% increase from previous year)
  • Annual P/Operating CF for 2019 was 56.23 (a 15.99% increase from previous year)
  • Annual P/Operating CF for 2018 was 48.48 (a -57.71% decrease from previous year)
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of Anika Therapeutics Inc.

Most recent P/Operating CFof ANIK including historical data for past 10 years.

Interactive Chart of P/Operating CF of Anika Therapeutics Inc.

Anika Therapeutics Inc. P/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 249.63 130.95 -285.95
2020 235.8 77.63 150.15 392.9 235.8
2019 56.23 76.84 102.96 50.96 56.23
2018 48.48 54.89 108.05 73.87 48.48
2017 114.64 70.86 114.78 40.96 114.64
2016 121.21 61.84 -801.96 82.7 121.21
2015 35.35 53.49 45.34 154.03 35.35
2014 40.53 73.26 160.49 43.71 40.53
2013 67.15 43.43 65.62 32.23 67.15
2012 27.39 91.01 37.75 -103.38 27.39
2011 16.64 23.43 -64.88 88.42 16.64
2010 0.0 0.0

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.